The proliferation of TF-1 cells treated with increasing concentrations of hIL-4 #8919 was assessed. After 72 hr, cells were incubated with a tetrazolium salt and the OD450 was determined.Learn more about how we get our images
The ability of Human IL-4 Neutralizing (D20H1) Rabbit mAb to inhibit hIL-4-induced TF-1 cell proliferation was assessed. Cells were incubated with increasing concentrations of antibody in the presence of hIL-4 #8919 (500 pg/ml). After 72 hr, viable cells were detected by incubation with a tetrazolium salt and the OD450 was determined.Learn more about how we get our images
Cell Signaling Technology recommends incubation of the neutralizing antibody with the intended target for 1 hr at 37ºC before addition to the experiment at an optimal concentration determined by the user.
Lyophilized from a 0.2 µm filtered solution in 10 mM HEPES with trehalose.
Store lyophilized material at -20ºC. After reconstitution, recommended storage at 4ºC for 1 month or -20ºC for 6 months. Avoid repeated freeze/thawing.
Human IL-4 Neutralizing (D20H1) Rabbit mAb binds to human IL-4 (hIL-4) and neutralizes its effects in a TF-1 cell proliferation assay. This antibody does not cross-react with mouse IL-4, human IL-13, or mouse IL-13.
Monoclonal antibody is produced by immunizing animals with a recombinant human IL-4 protein.
Neutralizing antibodies can be used to inhibit normal biological function through their binding to biological molecules. These reagents can be used to determine the effects that a particular molecule has in biological systems. Human IL-4 Neutralizing (D20H1) Rabbit mAb has been shown to neutralize the proliferation of TF-1 cells in vitro with an ND50 in the range of 3-19 ng/ml.
<0.1 EU/µg of antibody
Interleukin-4 (IL-4) is produced by T cells, NK T cells, γδ cells, and mast cells (1). Target cells include B cells, T cells, and macrophages (1). IL-4 induces differentiation of naive T cells into the Th2 phenotype. IL-4 also promotes B cell proliferation, antibody isotype switching, and expression of other Th2 cytokines including IL-5 and IL-9. IL-4-induced Th2 polarization is important in developing humoral immunity against extracellular pathogens (1) and is involved in the development of allergy and asthma (2). IL-4 binds to two distinct receptors, the type I receptor and type II receptor. The type I receptor is a heterodimer consisting of IL-4Rα chain and the common gamma chain, γc (3,4). The type II receptor, which is shared with IL-13, is a heterodimer of IL-4Rα and IL-13Rα1. Signaling initiated via type I receptor results in the activation of Jak1/Stat6, Jak3, and the PI3K/Akt pathways (3). The type II receptor activates the Jak1/Stat6 and the Tyk2/Stat3 pathways (3).
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
Explore pathways related to this product.
|11964S||100 µg||$ 338.0|